DK1501826T3 - Substituerede indoler som alpha-1-agonister - Google Patents

Substituerede indoler som alpha-1-agonister

Info

Publication number
DK1501826T3
DK1501826T3 DK03714714T DK03714714T DK1501826T3 DK 1501826 T3 DK1501826 T3 DK 1501826T3 DK 03714714 T DK03714714 T DK 03714714T DK 03714714 T DK03714714 T DK 03714714T DK 1501826 T3 DK1501826 T3 DK 1501826T3
Authority
DK
Denmark
Prior art keywords
agonists
alpha
substituted indoles
indoles
substituted
Prior art date
Application number
DK03714714T
Other languages
English (en)
Inventor
Saul Jaime-Figueroa
Lubica Raptova
Robert Greenhouse
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1501826T3 publication Critical patent/DK1501826T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK03714714T 2002-02-01 2003-01-23 Substituerede indoler som alpha-1-agonister DK1501826T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35350802P 2002-02-01 2002-02-01
US41849202P 2002-10-15 2002-10-15
PCT/EP2003/000644 WO2003064387A2 (en) 2002-02-01 2003-01-23 Substituted indoles as alpha-1 agonists

Publications (1)

Publication Number Publication Date
DK1501826T3 true DK1501826T3 (da) 2007-01-29

Family

ID=27669110

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03714714T DK1501826T3 (da) 2002-02-01 2003-01-23 Substituerede indoler som alpha-1-agonister

Country Status (18)

Country Link
US (1) US6852726B2 (da)
EP (1) EP1501826B1 (da)
JP (1) JP4209332B2 (da)
KR (1) KR100656037B1 (da)
CN (1) CN100378095C (da)
AR (1) AR038341A1 (da)
AT (1) ATE340792T1 (da)
AU (1) AU2003218962B2 (da)
BR (1) BR0307406A (da)
CA (1) CA2473803A1 (da)
DE (1) DE60308670T2 (da)
DK (1) DK1501826T3 (da)
ES (1) ES2271551T3 (da)
MX (1) MXPA04007414A (da)
PL (1) PL373410A1 (da)
PT (1) PT1501826E (da)
RU (1) RU2337909C2 (da)
WO (1) WO2003064387A2 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
MXPA05004929A (es) 2002-11-07 2005-08-18 Akzo Nobel Nv Indoles utiles en el tratamiento de enfermedades relacionadas a receptor de androgeno.
UA79504C2 (en) * 2002-11-07 2007-06-25 Organon Nv Indols for treating diseases associated with androgen receptors
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
CA2523253C (en) * 2003-05-09 2010-06-22 F. Hoffmann-La Roche Ag Methyl indoles and methyl pyrrolopyridines as alpha-1 adrenergic agonists
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) * 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
JP2007508363A (ja) * 2003-10-14 2007-04-05 オキサジェン リミテッド Crth2アンタゴニスト活性を有する化合物
JP4448730B2 (ja) * 2004-04-20 2010-04-14 富士フイルム株式会社 感光性組成物、該感光性組成物に用いられる化合物及び該感光性組成物を用いたパターン形成方法
TW200602317A (en) * 2004-04-23 2006-01-16 Akzo Nobel Nv Novel androgens
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
ATE517085T1 (de) 2004-11-23 2011-08-15 Astrazeneca Ab Zur behandlung von atemwegserkrankungen geeignete phenoxyessigsäurederivate
US7531568B2 (en) 2004-11-30 2009-05-12 Plexxikon, Inc. PPAR active compounds
JP2008521831A (ja) * 2004-11-30 2008-06-26 プレキシコン,インコーポレーテッド Ppar活性化合物
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
DK2839830T3 (da) * 2005-01-14 2019-08-19 Urigen Inc Kits og sammensætninger til behandling af lidelser i de nedre urinveje
EP1917330A2 (en) * 2005-08-22 2008-05-07 Shell Internationale Researchmaatschappij B.V. A diesel fuel and a method of operating a diesel engine
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
WO2007039736A1 (en) 2005-10-06 2007-04-12 Astrazeneca Ab Novel compounds
CN101460458A (zh) * 2006-02-15 2009-06-17 阿勒根公司 具有1-磷酸-鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚-3-羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物
CA2642668C (en) * 2006-02-15 2013-01-08 Allergan, Inc. Indole-3-carboxylic acid amide and ester compounds bearing phenyl groups having sphingosine-1-phosphate (s1p) receptor antagonist biological activity
JP2009538289A (ja) 2006-05-26 2009-11-05 アストラゼネカ・アクチエボラーグ ビアリールまたはヘテロアリール置換インドール
PE20090159A1 (es) 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
KR101493554B1 (ko) * 2008-05-05 2015-02-16 론자 아게 (론자 엘티디.) 구아니디노 및 아미노기 보호용 인돌술포닐 보호기
CA2797281A1 (en) * 2010-05-06 2011-11-10 Merck Sharp & Dohme Corp. Aza-indole derivatives useful as modulators of faah
TWI695831B (zh) * 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Crth2拮抗劑化合物及其用途
CN106674081A (zh) * 2016-12-18 2017-05-17 南京理工大学 一种3‑甲硫基吲哚衍生物合成方法
WO2020150439A1 (en) * 2019-01-17 2020-07-23 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
US12459938B2 (en) 2019-03-04 2025-11-04 Beth Israel Deaconess Medical Center, Inc. ORAI channel inhibitors
CN114835678A (zh) * 2021-02-02 2022-08-02 广东东阳光药业有限公司 吲哚衍生物的盐及其用途
CN114989136A (zh) * 2021-02-02 2022-09-02 广东东阳光药业有限公司 吲哚衍生物的盐及其用途
WO2022166638A1 (zh) * 2021-02-02 2022-08-11 广东东阳光药业有限公司 吲哚衍生物的盐及其用途
AU2023240170A1 (en) * 2022-03-24 2024-10-31 Curasen Therapeutics, Inc. Alpha 1a-adrenergic receptor agonists and methods of use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3404156A (en) 1966-02-23 1968-10-01 Sterling Drug Inc Imidazolin-2-yl-alkyl-substituted indoles
US3689655A (en) 1970-12-07 1972-09-05 Sterling Drug Inc Rodenticidal and rodent repellent compositions
US4654360A (en) 1984-06-01 1987-03-31 Syntex (U.S.A.) Inc. 1,2,3-trisubstituted indoles for treatment of inflammation
US5095031A (en) 1990-08-20 1992-03-10 Abbott Laboratories Indole derivatives which inhibit leukotriene biosynthesis
US5334597A (en) 1991-10-17 1994-08-02 Merck Frosst Canada, Inc. Indole carbamates as leukotriene antagonists
ZA939516B (en) 1992-12-22 1994-06-06 Smithkline Beecham Corp Endothelin receptor antagonists
US6175013B1 (en) 1994-06-10 2001-01-16 Eli Lilly And Company Imidazolinyl tachykinin receptor antagonists
DE19514579A1 (de) * 1995-04-20 1996-10-24 Boehringer Ingelheim Kg Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz
FR2735774B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
AU717422B2 (en) 1995-09-01 2000-03-23 Eli Lilly And Company Indolyl neuropeptide Y receptor antagonists
GB9600235D0 (en) * 1996-01-05 1996-03-06 Pfizer Ltd Therapeutic agents
SG72827A1 (en) 1997-06-23 2000-05-23 Hoffmann La Roche Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives
AU2201699A (en) 1997-12-19 1999-07-12 Eli Lilly And Company Hypoglycemic imidazoline compounds
GB9910110D0 (en) * 1999-04-30 1999-06-30 Glaxo Group Ltd Chemical compounds
US6323231B1 (en) 2000-02-17 2001-11-27 Abbott Laboratories Use of α1A adrenoceptor agonists with α1B and α1D antagonism for the treatment of stress urinary incontinence

Also Published As

Publication number Publication date
DE60308670D1 (de) 2006-11-09
KR100656037B1 (ko) 2006-12-11
US20030220319A1 (en) 2003-11-27
MXPA04007414A (es) 2004-10-11
PT1501826E (pt) 2007-01-31
CA2473803A1 (en) 2003-08-07
AU2003218962B2 (en) 2008-09-25
JP2005522427A (ja) 2005-07-28
CN100378095C (zh) 2008-04-02
EP1501826A2 (en) 2005-02-02
RU2004126613A (ru) 2005-07-10
AR038341A1 (es) 2005-01-12
US6852726B2 (en) 2005-02-08
ATE340792T1 (de) 2006-10-15
WO2003064387A2 (en) 2003-08-07
EP1501826B1 (en) 2006-09-27
DE60308670T2 (de) 2007-08-16
WO2003064387A3 (en) 2004-12-02
BR0307406A (pt) 2004-12-28
ES2271551T3 (es) 2007-04-16
JP4209332B2 (ja) 2009-01-14
KR20040077927A (ko) 2004-09-07
RU2337909C2 (ru) 2008-11-10
CN1628113A (zh) 2005-06-15
PL373410A1 (en) 2005-08-22

Similar Documents

Publication Publication Date Title
NO20044654L (no) Piperidinoylpiperidiner som 5-HTIF-agonister
DE60308670D1 (de) Substituierte indole als alpha-1 agonisten
IS7607A (is) Ný útskipt indól
DK1492785T3 (da) 2-hydroxy-3-heteroarylindol-derivater som GSK3-inhibitorer
NO20052887D0 (no) Pyridazinonderivater som GSK-3Beta inhibitorer.
NO20055680D0 (no) Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
SI1398328T1 (sl) Hidroksialkilni derivati ĺ kroba
ATE392206T1 (de) Indolderivate als beta-2 agonisten
ATE460418T1 (de) Heterocyclocarboxamidderivate
ATE450506T1 (de) Indol-3-schwefelderivate
NO20051042L (no) Pyrimidylsulfonamidderivater som kemokinreseptormodulatorer
NO20052802D0 (no) Pyrrolopyrimidinderivativer
DE10393374D2 (de) Zusammensetzung
NO20050665L (no) Pyrrolidonderivater som MAOE inhibitoere
DK1438289T3 (da) Indolderivater som cox II-inhibitorer
DE60305332D1 (de) IMIDAZOi1,2-AöPYRIDINE
DK1556377T3 (da) Cyclopropylthienylcarboxamider som fungicider
ATE335729T1 (de) 3h-chinazoline -4-on derivaten
SE0500163L (sv) Sammansättning
ATE423771T1 (de) Tetrahydrochinolinderivate
DE60324018D1 (de) Agonisten
DK1499622T3 (da) Meterotricyclyl-6-alkylidenpenemer som beta-lactamaseinhibitorer
NO20051500D0 (no) Substituerte heterocyklylpyrimidiner.
EP1561467A4 (en) COMPOSITION FOR RECOVERING DAMAGED SKIN
NO20043610L (no) Fenylpyrimidinaminer som IgE inhibitorer